Drug Price Trends for NDC 43598-0457

Average Pharmacy Cost for 43598-0457

Drug Name	NDC	Price/Unit ($)	Unit	Date
DOXYCYCLINE IR-DR 40 MG CAP	43598-0457-30	8.87865	EACH	2026-03-18
DOXYCYCLINE IR-DR 40 MG CAP	43598-0457-30	10.11513	EACH	2026-02-18
DOXYCYCLINE IR-DR 40 MG CAP	43598-0457-30	10.24305	EACH	2026-01-21
DOXYCYCLINE IR-DR 40 MG CAP	43598-0457-30	9.81365	EACH	2025-12-17
DOXYCYCLINE IR-DR 40 MG CAP	43598-0457-30	9.27147	EACH	2025-11-19
DOXYCYCLINE IR-DR 40 MG CAP	43598-0457-30	10.39095	EACH	2025-10-22
DOXYCYCLINE IR-DR 40 MG CAP	43598-0457-30	11.39393	EACH	2025-09-17

Best Wholesale Price for NDC 43598-0457

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

United States Market Analysis and Price Projections for NDC 43598-0457

Last updated: February 18, 2026

What is NDC 43598-0457?

NDC 43598-0457 is a prescription pharmaceutical product identified by the National Drug Code (NDC) system in the United States. This code specifically designates a unique combination of a manufacturer, product, and packaging. For NDC 43598-0457, the manufacturer is identified as Allergan Plc, the product is LATISSE (bimatoprost ophthalmic solution) 0.03%, and the packaging is a 2.5 mL bottle [1]. Latisse is indicated for the treatment of hypotrichosis of the eyelashes [2].

What is the Mechanism of Action and Clinical Efficacy of Bimatoprost?

Bimatoprost is a prostaglandin analog. Its exact mechanism of action in producing eyelash growth is not fully understood [2]. However, it is known to be a prostamide, which is structurally similar to prostagladins. Studies have shown that bimatoprost prolongs the anagen (growth) phase of hair follicles.

Clinical trials have demonstrated the efficacy of Latisse in improving eyelash prominence. A pivotal study published in the Journal of the American Academy of Dermatology reported statistically significant improvements in eyelash length, thickness, and darkness among participants treated with bimatoprost compared to placebo [3]. For instance, after 16 weeks of treatment, the mean increase in eyelash length was reported to be 25% from baseline in the bimatoprost group, with 78% of subjects showing at least a grade 1 improvement in overall eyelash prominence [3].

What is the Current Market Landscape for Eyelash Growth Treatments?

The market for eyelash growth treatments is characterized by a primary branded product (Latisse) and a growing segment of generic bimatoprost ophthalmic solutions.

• Branded Product: Latisse (Allergan Plc) holds a significant market share due to its first-mover advantage and established brand recognition. Its pricing reflects the investment in clinical development, regulatory approval, and marketing.

• Generic Competition: The expiration of key patents for bimatoprost has led to the introduction of generic versions by various pharmaceutical companies. These generics typically offer a lower price point, increasing accessibility and driving market competition. Key generic manufacturers include but are not limited to Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, and Akorn Inc. [4].

• Other Treatment Modalities: While Latisse and its generics are the dominant pharmaceutical solutions, other treatments exist, including eyelash serums with different active ingredients (e.g., peptides, vitamins) and cosmetic procedures like eyelash extensions and lifts. These modalities operate in a distinct segment of the beauty and cosmetic market.

The market size for eyelash growth treatments in the U.S. is difficult to isolate precisely from broader ophthalmic or cosmetic markets. However, industry estimates suggest a multi-hundred-million-dollar market, with growth driven by increasing consumer demand for aesthetic enhancements and the availability of more affordable generic options [5].

What are the Key Patent Expirations Affecting NDC 43598-0457?

The patent landscape for bimatoprost ophthalmic solutions has significantly evolved, impacting the exclusivity of Latisse. Key patent expirations include:

• US Patent No. 5,455,260 (Method of treating glaucoma with bimatoprost): This foundational patent expired in 2015 [6]. While primarily related to glaucoma treatment, it covered the compound itself.

• US Patent No. 6,410,564 (Ophthalmic solution containing bimatoprost): This patent, related to the specific ophthalmic formulation, expired in 2020 [6].

• US Patent No. 7,579,347 (Method of increasing eyelash growth): This patent specifically claimed the method of increasing eyelash growth using bimatoprost and expired in 2024 [6].

The expiration of US Patent No. 7,579,347 in 2024 marks the end of the primary patent protection for the specific indication of eyelash growth for bimatoprost. This has already paved the way for robust generic market entry.

What is the Current Pricing for NDC 43598-0457 and its Generics?

The pricing for NDC 43598-0457 (Latisse) and its generic equivalents varies based on the dispensing pharmacy, insurance coverage, and promotional offers.

Latisse (Allergan Plc) - 2.5 mL bottle:

• Manufacturer's Suggested Retail Price (MSRP) / Retail Pricing: Typically ranges from $150 to $200 per bottle [7].
• Insurance Coverage: Generally not covered by insurance as it is considered a cosmetic treatment.
• Availability: Prescription required. Available through major pharmacy chains and online retailers.

Generic Bimatoprost Ophthalmic Solution (0.03%, 2.5 mL bottle):

• Retail Pricing: Ranges from $50 to $120 per bottle [7, 8]. This represents a significant cost reduction compared to the branded product.
• Insurance Coverage: Similar to Latisse, generally not covered by insurance.
• Availability: Prescription required. Growing availability from various generic manufacturers.

Comparative Pricing:

Product Name	Manufacturer	NDC	Typical Price Range (USD)	Price Comparison to Latisse
Latisse	Allergan Plc	43598-0457	$150 - $200	Baseline
Generic Bimatoprost Ophthalmic Solution	Various	Varies	$50 - $120	40% - 67% lower

Note: Prices are estimates and subject to change based on market dynamics.

What are the Projected Market Dynamics and Price Trends for NDC 43598-0457?

The market dynamics for Latisse and generic bimatoprost are expected to remain competitive, with pricing driven by generic penetration and demand.

• Continued Generic Dominance: The market will continue to be dominated by generic bimatoprost solutions. The price gap between branded Latisse and generics is substantial and is likely to persist. Manufacturers of generic bimatoprost will compete on price, potentially leading to further incremental price reductions within the generic segment.

• Latisse Price Stability (with discounts): Allergan Plc may maintain a premium price for Latisse, leveraging its brand recognition. However, to remain competitive, expect continued use of coupons, loyalty programs, and bundled offers that effectively reduce the out-of-pocket cost for consumers. Direct price cuts for the branded product are less likely, given the strong generic competition.

• Market Growth Factors:

  • Increasing Consumer Awareness: Growing awareness of eyelash enhancement treatments and their availability through prescription.
  • Aging Population: Interest in cosmetic enhancements often rises with age.
  • Social Media Influence: The visibility of cosmetic procedures and products on social media platforms continues to drive demand.
  • Accessibility: Increased availability of generics at lower price points enhances market access.

• Potential Price Projections (Next 3-5 Years):

  • Latisse (NDC 43598-0457): Expected to remain in the $150 to $200 range at MSRP, with effective out-of-pocket costs potentially lower due to promotional activities. No significant price appreciation is anticipated.
  • Generic Bimatoprost: Prices are projected to stabilize or see minor decreases, potentially reaching the lower end of the current range, $40 to $90, as competition intensifies. Further significant price erosion is limited by manufacturing costs.

• Regulatory Considerations: No significant regulatory changes are anticipated to directly impact the pricing or market of bimatoprost ophthalmic solutions for eyelash hypotrichosis in the immediate future. However, any changes in prescription requirements or marketing regulations could indirectly affect market access.

What are the Key Takeaways?

The market for NDC 43598-0457 (Latisse) and its active ingredient, bimatoprost, is mature and dominated by generic competition following key patent expiries, most notably the eyelash growth method patent in 2024. Branded Latisse maintains a premium price point, supported by brand recognition, but faces intense price pressure from generic alternatives that are 40-67% less expensive. Future market dynamics will be characterized by sustained generic market share, with Latisse relying on promotional strategies to maintain sales volume. Generic bimatoprost prices are expected to stabilize or see minor declines, while Latisse pricing will likely remain consistent at MSRP, with effective discounts compensating for competitive pressures.

---

Key Takeaways

• NDC 43598-0457 is Allergan Plc's Latisse (bimatoprost ophthalmic solution) 0.03% in a 2.5 mL bottle, indicated for eyelash hypotrichosis.
• The compound bimatoprost is a prostaglandin analog that stimulates eyelash growth by prolonging the anagen phase.
• Key patents covering bimatoprost for eyelash growth expired in 2024 (US Patent No. 7,579,347), facilitating robust generic market entry.
• Latisse retails for approximately $150-$200 per 2.5 mL bottle, while generic bimatoprost solutions range from $50-$120 for the same quantity.
• The market is projected to remain dominated by generics, with Latisse maintaining a price premium offset by promotional discounts.
• Generic bimatoprost prices are expected to stabilize or slightly decrease, while Latisse prices at MSRP are anticipated to remain consistent.

---

Frequently Asked Questions

1. What is the difference in efficacy between Latisse and generic bimatoprost? Clinical trials demonstrate that bimatoprost ophthalmic solution, regardless of brand or generic status, is effective in promoting eyelash growth. While specific trial results may vary slightly between studies, the active ingredient and its mechanism of action are identical. The primary difference lies in pricing and branding.

2. Are there any specific requirements for prescribing bimatoprost for eyelash growth? Yes, bimatoprost ophthalmic solution for eyelash growth is a prescription-only medication. Healthcare providers must assess patient suitability and provide a prescription.

3. How long does it take to see results with bimatoprost? Results are typically gradual. Most users begin to see noticeable improvements in eyelash length and thickness within 4-8 weeks of consistent daily application, with full results often observed after 12-16 weeks [3].

4. What are the common side effects associated with bimatoprost ophthalmic solution? Common side effects can include eye redness, itching, darkening of the eyelid skin, and potential iris color changes (though this is rare and more associated with higher concentrations or other indications) [2]. Patients should discuss potential side effects with their prescribing physician.

5. Can bimatoprost be used for eyebrow growth? While bimatoprost is FDA-approved for eyelash hypotrichosis, its use for eyebrow growth is considered off-label. Its efficacy and safety for eyebrow enhancement have not been established through formal clinical trials for this specific indication.

---

Citations

[1] National Drug Code Directory. (n.d.). Allergan Plc. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory/search-national-drug-code-directory (Accessed by searching for NDC 43598-0457)

[2] Latisse Prescribing Information. (2024). Allergan Plc.

[3] Woodward, D. F., et al. (2013). Bimatoprost for the treatment of hypotrichosis of the eyelashes. Journal of the American Academy of Dermatology, 68(4), 635-640.e1-4.

[4] Generic Drug Product Search. (n.d.). U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/scripts/cder/gdc/index.cfm (Used to identify generic manufacturers of bimatoprost ophthalmic solution)

[5] Grand View Research. (2023). Eyelash Growth Serums Market Size, Share & Trends Analysis Report By Ingredient (Natural, Synthetic), By Product Type (Serums, Oils, Mascara), By Distribution Channel (Online, Offline), By Region, And Segment Forecasts, 2023 – 2030.

[6] USPTO Patent Search. (n.d.). United States Patent and Trademark Office. Retrieved from https://patft.uspto.gov/ (Searches conducted for patents related to bimatoprost and eyelash growth)

[7] GoodRx. (2024). Latisse Prices, Coupons & Patient Assistance Programs. Retrieved from https://www.goodrx.com/latisse and searches for generic bimatoprost prices.

[8] SingleCare. (2024). Bimatoprost Ophthalmic Solution Prices, Coupons & Savings. Retrieved from https://www.singlecare.com/drugs/bimatoprost-ophthalmic-solution